Ala Altaie: We Found That Mononuclear Cells From RA Patients Can Trigger Clot Formation
Ala Altaie, Research Fellow in Mesenchymal Stem Cell Biology at the Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, shared a post on LinkedIn:
”New paper out!
Why do some patients on JAK inhibitors develop venous thromboembolism (VTE) or pulmonary embolism (PE) without deep vein thrombosis?
In our latest study led by Paula David and colleagues, we found that mononuclear cells from RA patients can trigger clot formation—especially when exposed to JAK inhibitors like tofacitinib.
This process, known as immunothrombosis, links the immune system to coagulation through increased Factor III production.
Panel A: Clots formed faster with tofacitinib
Panel B: Clot strength was higher
These findings shed light on the immune–coagulation connection behind JAK inhibitor–associated clots.
Read more.”
Title: Augmentation of immunothrombosis as a key mechanism underlying JAK inhibition associated hypercoagulability in rheumatoid arthritis
Authors: Paula David, Tom Macleod, Ala Altaie, Yu Shi, Kerem Abacar, Sami Giryes, Gabrielle de Mello Santos, Payal Ganguly, Mark Harland, Chi Wong, Andrew Scarsbrook, Paul Emery, Kulveer Mankia, Shouvik Dass, Andrea Di Matteo, Benazir Saleem, Cédric Duval, Robert Ariëns, Dennis McGonagle
Stay updated with Hemostasis Today.
-
Mar 12, 2026, 20:44Honoring Marion Stolte’s Lasting Impact on the Bleeding Disorders Community – WFH
-
Mar 12, 2026, 20:37Paul Riley: Is Thrombin Generation Assay Ready for Prime Time?
-
Mar 12, 2026, 20:28Rob Maloney: Building Visibility for Bleeding Disorders in Rural Georgia
-
Mar 12, 2026, 20:19Akshat Jain: Validating Oral Pain Medication Use as a Global Marker in Sickle Cell Disease
-
Mar 12, 2026, 20:13Michael Makris: Early Clinical Results of AAV8-BDD FVIII Gene Therapy in Hemophilia A
-
Mar 12, 2026, 20:02Wolfgang Miesbach: From Heparin to Vaccines – The Expanding Biology of Anti-PF4 Immunothrombosis
-
Mar 12, 2026, 19:56Christophe Dubois: Celebrating Nicolas Gendron’s HDR Defense and Future in Hemostasis
-
Mar 12, 2026, 17:06Caitlin Raymond: Managing Crigler–Najjar Syndrome Type 1 Crisis Without a Standard TPE Protocol
-
Mar 12, 2026, 17:03Jan Sloves: Insights on Comprehensive Venous Duplex Imaging at VEITH Symposium 2025